BSE filing, NSE: VIJAYA. Summary written from the filing by ALFA Finder's alert engine.
Vijaya Diagnostic Centre Ltd: key numbers
- Share price
- ₹1,468.60
- Market cap
- ₹15,126 Cr
- Revenue (annual)
- ₹814.2 Cr
- Net profit (annual)
- ₹173.0 Cr
- P/E (TTM)
- 74.3×Sector 53.9×
- Promoter holding
- 52.46%-0.05% QoQ
- FII holding
- 10.67%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vijaya Diagnostic Centre Ltd
All →Vijaya Diagnostic Centre Earnings Call Transcript: Key Takeaways
Vijaya Diagnostic delivered strong Q2 growth, leveraging operating leverage and CGHS tariff revisions to expand margins significantly despite aggressive network expansion.
- Call
- Guides 20% growth
Vijaya Diagnostic Centre Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹2,554 Mn (+26.7%), EBITDA ₹1,128 Mn (44.1% margin), PAT ₹595 Mn (23.3%). Strategy: hub-and-spoke densification, Bengaluru/Hyderabad hubs, Guwahati entry.
Vijaya Diagnostic Centre Results Update
Vijaya Diagnostic's Q2 FY27 press release reports revenue up 26.7% and PAT up 37.4% year-on-year. It also notes an agreement to acquire Arya Wellness Centre in Guwahati.
Vijaya Diagnostic Centre Management Change
Vijaya Diagnostic Centre appointed Rahul Jain as Company Secretary and Compliance Officer, designated KMP, effective November 03, 2026. The appointment follows the Nomination and Remuneration Committee's recommendation.
Vijaya Diagnostic Centre Q2 FY27 Results: Net Profit ₹59.5 Cr, Up 37.4% YoY
Vijaya Diagnostic Centre Ltd reported revenue from operations of ₹255.4 Cr (+26.7% YoY) and net profit of ₹59.5 Cr (+37.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹59.5 Cr · +37.4% YoY
Vijaya Diagnostic Centre Board Meeting Date
Vijaya Diagnostic Centre scheduled a board meeting for 3 Nov 2026 to approve unaudited Q1 and H1 FY27 results. No financial figures or material decisions are disclosed in this notice.
Other business update announcements
All →Italian Edibles Business Update
Italian Edibles revised its project timeline again, pushing commercial production from January 2027 to April 2027. Construction delays stem from steel prices, supply chain disruption, weather and labour shortages.
- Execution
- Commercial production revised to April 2027 from January 2027
Bajaj Finserv Business Update
Bajaj Finserv disclosed October 2026 monthly premium and new business data for its unlisted insurance subsidiaries. The figures are provisional.
Bajaj Finance Business Update
Bajaj Finance submitted its Half Yearly Report for FY2026-27 covering the six months to 30 September 2026. The report shows 28% consolidated PAT growth to ₹12,447 crore and a planned ₹17,500 crore capital raise.
Cohance Lifesciences Business Update
Cohance Lifesciences disclosed that USFDA issued the Establishment Inspection Report for its Pashamylaram facility, classifying the inspection as Voluntary Action Indicated. The inspection is now concluded.
Religare Enterprises Business Update
Religare Finvest, a material subsidiary, resumed lending after RBI lifted its Corrective Action Plan. It disbursed its first Loan Against Property on 6 November 2026.
Purple Wave Infocom Business Update
Purple Wave signed a 5-year data integration agreement with BPCL for its Hygiair devices. The Rs 10 crore figure is indicative, not firm order value.
- Execution
- 5 years